Literature DB >> 19435362

Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

Julia Beuttler1, Miriam Rothdiener, Dafne Müller, Fredrik Y Frejd, Roland E Kontermann.   

Abstract

Affibody molecules are small and stable antigen-binding molecules derived from the B domain of protein A. We applied a bivalent, high-affinity epidermal growth factor receptor (EGFR)-specific affibody molecule for the generation of targeted PEGylated liposomes. These sterically stabilized affibody liposomes (SAL) were produced by chemical coupling of the cysteine-modified affibody molecule to maleimide-PEG(2000)-DSPE and subsequent insertion into PEGylated liposomes. These SAL showed strong and selective binding to EGFR-expressing tumor cell lines. Binding was dependent on the amount of inserted affibody molecule-lipid conjugates and could be blocked by soluble EGF. Approximately 30% of binding activity was still retained after 6 days of incubation in human plasma at 37 degrees C. Binding of SAL to cells led to efficient internalization of the liposomes. Using mitoxantrone-loaded liposomes, we observed for SAL, compared to untargeted liposomes, an enhanced cytotoxicity toward EGFR-expressing cells. In summary, we show that SAL can be easily prepared from affibody molecules and thus may be suitable for the development of carrier systems for targeted delivery of drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435362     DOI: 10.1021/bc900061v

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

2.  Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor.

Authors:  Jonathan K Pokorski; Marisa L Hovlid; M G Finn
Journal:  Chembiochem       Date:  2011-09-29       Impact factor: 3.164

3.  Recombinant and chemo-/bio-orthogonal synthesis of liposomal thrombomodulin and its antithrombotic activity.

Authors:  Lin Wang; Rui Jiang; Yang Liu; Maosheng Cheng; Qingyu Wu; Xue-Long Sun
Journal:  J Biosci Bioeng       Date:  2017-07-08       Impact factor: 2.894

Review 4.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.

Authors:  Anu Puri; Kristin Loomis; Brandon Smith; Jae-Ho Lee; Amichai Yavlovich; Eliahu Heldman; Robert Blumenthal
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2009       Impact factor: 4.889

5.  Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).

Authors:  Brandon Smith; Ilya Lyakhov; Kristin Loomis; Danielle Needle; Ulrich Baxa; Amichai Yavlovich; Jacek Capala; Robert Blumenthal; Anu Puri
Journal:  J Control Release       Date:  2011-04-09       Impact factor: 9.776

6.  Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

Authors:  Yingna He; Linhua Zhang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2010-09-20

Review 7.  Receptor-targeted nanocarriers for therapeutic delivery to cancer.

Authors:  Bo Yu; Heng Chiat Tai; Weiming Xue; L James Lee; Robert J Lee
Journal:  Mol Membr Biol       Date:  2010-10       Impact factor: 2.857

8.  Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo.

Authors:  V O Shipunova; S M Deyev
Journal:  Acta Naturae       Date:  2022 Jan-Mar       Impact factor: 2.204

9.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

10.  Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody.

Authors:  Tatiana S Karyagina; Alexey V Ulasov; Tatiana A Slastnikova; Andrey A Rosenkranz; Tatiana N Lupanova; Yuri V Khramtsov; Georgii P Georgiev; Alexander S Sobolev
Journal:  Front Pharmacol       Date:  2020-03-04       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.